To access the full text documents, please follow this link: http://hdl.handle.net/2445/119830

Title:	Development of cutaneous toxicities during selective anti-BRAF therapies: preventive role of combination with MEK inhibitors
Author:	Erfan, Gamze; Puig i Sardà, Susana; Carrera Álvarez, Cristina; Arance, Ana; Gaba, Lydia; García Herrera, Adriana; Alós i Hernández, Llúcia; Malvehy, J. (Josep)
Notes:	Activated BRAF mutations affecting the mitogen-activated protein kinases (MAPK) pathway are present in 50% of metastatic melanomas. Targeted therapies have been developed to block such mutations (1, 2). There is a risk of other components of the MAPK signalling pathway, such as MEK, being reactivated after the use of BRAF inhibitors (3-5). Given the evidence of drug resistance and side-effects of BRAF inhibitors, combined treatments with BRAF and MEK inhibitors are being tested in clinical trials for metastatic melanoma. Trametinib is one of these MEK inhibitors. Skin toxicities from BRAF inhibitors, such as photosensitivity, palmoplantar keratoderma (PPK) and keratosis pilaris (KP), have been reported (4, 6-11). Also, non-melanoma skin cancers (NMSC) are considered one of the most significant sideeffects (3, 11). We report here the profile of skin toxicities from vemurafenib, dabrafenib alone, or dabrafenib and trametinib combined treatment.
Subject(s):	-Proteïnes quinases -Melanoma -Protein kinases -Melanoma
Rights:	(c) Erfan, Gamze et al., 2017
Document type:	Article Article - Published version
Published by:	Society for the Publication of Acta Dermato-Venereologica
Share:

Show full item record